| Name | Scancell Holdings |
|---|---|
| Epic | SCLP |
| Isin | GB00B63D3314 |
| Index | MID300 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 10.05p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £104.20 | Debt ratio | n/a |
| Shares in issue | 927.98 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -51.24 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -0.68 | 52-week high / low | 8.92p / 19.50p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Scancell Holdings |
|---|---|
| Address | Bellhouse Building, Sanders Road, Oxford Science Park, Oxford, United Kingdom, OX4 4GD |
| Telephone | |
| Website | http://www.scancell.co.uk/ |
| Director | Position |
|---|---|
| Dr Phil L'Huillier | CEO |
| Mr Sath Nirmalananthan | CFO |
| Mr Martin Diggle | Non-Executive Director |
| Dr. Florian Reinaud | Non-Executive Director |
| Ms Ursula Ney | Non-Executive Director |
| Ms Susan Clement Davies | Deputy Chairman |
| Mr Jean-Michel Cosséry | Non-Executive Chairman |
| Professor Lindy Durrant | Chief Scientific Officer |
| Assets £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Reporting date | 30/04/24 | 30/04/23 | 30/04/22 |
| Intangible asssets and goodwill | n/a | n/a | 3.42 |
| Investments and other non-current assets | n/a | n/a | n/a |
| Total non-current assets | 1.71 | 2.25 | 6.16 |
| Inventory / work in progress | n/a | n/a | n/a |
| Trade and other receivables | 7.05 | 4.69 | 0.65 |
| Cash and equivalents | 14.82 | 19.92 | 28.73 |
| Other current assets and asset held for resale | n/a | n/a | 2.99 |
| Total of all assets | 23.58 | 26.86 | 38.52 |
| Liabilities £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Short term liabilities | 6.39 | 7.97 | 2.45 |
| Long term liabilities | 20.69 | 28.53 | 31.26 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 27.08 | 36.5 | 33.71 |
| Net assets £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net assets | -3.5 | -9.65 | 4.81 |
| Equity £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Share capital | 0.93 | 0.82 | 0.81 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | -84.19 | -78.33 | -62.42 |
| Share premium account | 71.93 | 60.7 | 65.02 |
| Total equity | -3.5 | -9.65 | 4.81 |
| Income £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -18.27 | -11.92 | -13.3 |
| Pre-tax profit | -9.12 | -14.3 | -6.27 |